Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
Bioxytran (OTCQB: BIXT) has announced a potential breakthrough in treating Bird Flu (H5N1) in egg-laying chickens through a new water-soluble galectin antagonist currently in preclinical trials. The treatment aims to prevent the need for mass culling during outbreaks by blocking viral entry into cells.
The company's approach leverages galectin antagonists that neutralize the virus by blocking viral adhesion, a mechanism previously demonstrated in Phase 2 human clinical trials and in vitro tests. The carbohydrate-based treatment targets viral spike proteins, preventing them from connecting to cells, potentially offering immediate containment of outbreaks.
This development could significantly impact the poultry industry, which currently faces billions in annual losses due to Bird Flu outbreaks and mandatory culling protocols. Bioxytran is actively seeking partnerships with organizations and government agencies to accelerate the treatment's development and deployment.
Bioxytran (OTCQB: BIXT) ha annunciato una potenziale svolta nel trattamento dell'Influenza Aviaria (H5N1) nelle galline ovaiole attraverso un nuovo antagonista della galectina solubile in acqua attualmente in fase di sperimentazione preclinica. Il trattamento mira a prevenire la necessità di abbattimenti di massa durante le epidemie bloccando l'ingresso del virus nelle cellule.
L'approccio dell'azienda sfrutta antagonisti della galectina che neutralizzano il virus bloccando l'adesione virale, un meccanismo precedentemente dimostrato in trial clinici umani di Fase 2 e in test in vitro. Il trattamento a base di carboidrati mira alle proteine spike virali, impedendo loro di collegarsi alle cellule, offrendo potenzialmente un contenimento immediato delle epidemie.
Questo sviluppo potrebbe avere un impatto significativo sull'industria avicola, che attualmente affronta perdite annuali di miliardi a causa delle epidemie di Influenza Aviaria e dei protocolli di abbattimento obbligatorio. Bioxytran sta attivamente cercando partnership con organizzazioni e agenzie governative per accelerare lo sviluppo e il dispiegamento del trattamento.
Bioxytran (OTCQB: BIXT) ha anunciado un posible avance en el tratamiento de la Gripe Aviar (H5N1) en gallinas ponedoras a través de un nuevo antagonista de galectina soluble en agua que actualmente se encuentra en ensayos preclínicos. El tratamiento tiene como objetivo prevenir la necesidad de sacrificios masivos durante los brotes al bloquear la entrada del virus en las células.
El enfoque de la empresa aprovecha los antagonistas de galectina que neutralizan el virus al bloquear la adhesión viral, un mecanismo previamente demostrado en ensayos clínicos humanos de Fase 2 y en pruebas in vitro. El tratamiento a base de carbohidratos se dirige a las proteínas espiga virales, impidiendo que se conecten a las células, lo que podría ofrecer un contención inmediata de los brotes.
Este desarrollo podría tener un impacto significativo en la industria avícola, que actualmente enfrenta pérdidas anuales de miles de millones debido a los brotes de Gripe Aviar y los protocolos de sacrificio obligatorio. Bioxytran está buscando activamente asociaciones con organizaciones y agencias gubernamentales para acelerar el desarrollo y la implementación del tratamiento.
Bioxytran (OTCQB: BIXT)는 현재 전임상 시험 중인 수용성 갈렉틴 길항제를 통해 산란용 닭의 조류 인플루엔자(H5N1) 치료에 대한 잠재적인 돌파구를 발표했습니다. 이 치료법은 바이러스가 세포에 침입하는 것을 차단하여 발병 중 대량 도살의 필요성을 예방하는 것을 목표로 합니다.
회사의 접근 방식은 바이러스의 부착을 차단하여 바이러스를 중화하는 갈렉틴 길항제를 활용하며, 이는 이전에 2상 인간 임상 시험과 시험관 내 테스트에서 입증된 메커니즘입니다. 탄수화물 기반의 치료법은 바이러스 스파이크 단백질을 표적으로 하여 세포와 연결되는 것을 방지하여, 발병의 즉각적인 억제를 제공할 수 있습니다.
이 개발은 현재 조류 인플루엔자 발병과 의무적 도살 프로토콜로 인해 매년 수십억 달러의 손실을 겪고 있는 가금류 산업에 상당한 영향을 미칠 수 있습니다. Bioxytran은 치료법의 개발 및 배포를 가속화하기 위해 조직 및 정부 기관과의 파트너십을 적극적으로 모색하고 있습니다.
Bioxytran (OTCQB: BIXT) a annoncé une avancée potentielle dans le traitement de la Grippe Aviaire (H5N1) chez les poules pondeuses grâce à un nouvel antagoniste de galectine soluble dans l'eau actuellement en essais précliniques. Le traitement vise à éviter la nécessité de tueries massives lors des épidémies en bloquant l'entrée du virus dans les cellules.
L'approche de l'entreprise s'appuie sur des antagonistes de galectine qui neutralisent le virus en bloquant l'adhésion virale, un mécanisme précédemment démontré lors d'essais cliniques humains de Phase 2 et dans des tests in vitro. Le traitement à base de glucides cible les protéines de pointe virales, les empêchant de se connecter aux cellules, offrant potentiellement un confinement immédiat des épidémies.
Ce développement pourrait avoir un impact significatif sur l'industrie avicole, qui fait actuellement face à des milliards de pertes annuelles en raison des épidémies de Grippe Aviaire et des protocoles de tuerie obligatoires. Bioxytran recherche activement des partenariats avec des organisations et des agences gouvernementales pour accélérer le développement et le déploiement du traitement.
Bioxytran (OTCQB: BIXT) hat einen potenziellen Durchbruch bei der Behandlung der Vogelgrippe (H5N1) bei legenden Hühnern durch einen neuen wasserlöslichen Galektin-Antagonisten bekannt gegeben, der sich derzeit in der präklinischen Erprobung befindet. Die Behandlung zielt darauf ab, die Notwendigkeit von Massenschlachtungen während Ausbrüchen zu verhindern, indem der virale Eintritt in die Zellen blockiert wird.
Der Ansatz des Unternehmens nutzt Galektin-Antagonisten, die das Virus neutralisieren, indem sie die virale Adhäsion blockieren, ein Mechanismus, der zuvor in Phase-2-Studien mit Menschen und in vitro-Tests nachgewiesen wurde. Die kohlenhydratbasierte Behandlung zielt auf virale Spike-Proteine ab, um zu verhindern, dass sie sich mit Zellen verbinden, was potenziell eine sofortige Eindämmung von Ausbrüchen bieten könnte.
Diese Entwicklung könnte erhebliche Auswirkungen auf die Geflügelindustrie haben, die derzeit aufgrund von Vogelgrippeausbrüchen und verpflichtenden Schlachtprotokollen jährlich Milliardenverluste verzeichnet. Bioxytran sucht aktiv Partnerschaften mit Organisationen und Regierungsbehörden, um die Entwicklung und den Einsatz der Behandlung zu beschleunigen.
- Treatment could save billions in annual losses for poultry industry
- Technology previously validated in Phase 2 human clinical trials
- Potential to eliminate costly mass culling requirements
- Solution addresses a significant market need in global food supply chain
- Still in early preclinical trials phase
- Optimal delivery method not yet established
- Partnerships needed for development and deployment
- Effectiveness in chickens still theoretical based on mammalian model
New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks
BOSTON, MASSACHUSETTS, March 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, unveiled a potential game-changer in the fight against Highly Pathogenic Avian Influenza (HPAI), commonly known as Bird Flu. This innovative water-soluble galectin antagonist, currently in preclinical trials, could revolutionize how outbreaks are managed in egg-laying chickens, preventing mass culling and safeguarding the global food supply. Bioxytran’s treatment leverages galectin antagonists, a class of molecules designed to block viral entry into cells, by neutralizing the virus in egg-laying chickens. This approach could prevent the spread of H5N1 without the need for mass culling, a current requirement during outbreaks.
Galectin antagonists have shown their ability to block viral adhesion. This has been proven in Phase 2 human clinical trials and in vitro tests. The Company thinks this mechanism works the same in all mammals. This is the reason why the Company expects it to be very effective in chickens. While the Company is also working on establishing the optimal delivery method, it is actively seeking partnerships with organizations and government agencies to accelerate the development and deployment of this groundbreaking treatment.
“This breakthrough represents a significant step forward in our mission to combat viral diseases,” said David Platt, CEO of Bioxytran Inc. "By targeting the virus directly, we can protect both animal health and the global food supply. Our galectin antagonists block the spike proteins outside the cell. This may stop the spread of the disease right away. Our peer-reviewed study showed that our carbohydrate-based galectin antagonists attach to viral spike proteins. This stops the proteins from connecting to cells. This mechanism is found in all mammals and forms the basis of our research, which should eliminate the risk of possible mutations. Bird Flu outbreaks have devastating economic consequences, costing the poultry industry billions annually. Current protocols require the culling of entire flocks, leading to significant losses for farmers and disruptions in the food supply chain. Our treatment could eliminate the need for such drastic measures, offering a more sustainable solution. We are actively seeking partnerships.”
About H5N1
According to the US Department of Agriculture (USDA) there were 369 million egg producing chickens at the start of 2025 of which 304 million produce the United States domestic supply of table eggs.1 Last quarter more than 20 million egg-laying chickens were culled due to bird flu.2 Last year the Animal and Plant Health inspection Service said it spent
Sources
1https://downloads.usda.library.cornell.edu/usda-esmis/files/fb494842n/q524mj24t/z316rx705/ckeg0125.pdf
2https://www.unmc.edu/healthsecurity/transmission/2025/01/14/u-s-egg-industry-sees-record-chicken-deaths-from-bird-flu-outbreak/
3https://www.federalregister.gov/documents/2024/12/31/2024-31384/payment-of-indemnity-and-compensation-for-highly-pathogenic-avian-influenza#p-33
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures. The company has 3 platform technologies in glycovirology, cancer metastasis, and oxygen delivery. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What is Bioxytran's new treatment approach for Bird Flu (BIXT stock)?
How does BIXT's galectin antagonist technology work against Bird Flu?
What stage of development is Bioxytran's Bird Flu treatment (BIXT) in?
How could BIXT's Bird Flu treatment impact the poultry industry?
